Liminatus Pharma, Inc. (LIMNW) stock

LIMNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMN

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30

$0.04+0.00 (0.00%)

Close on Oct 30, 2026Market cap $189.39MP/E –Yield –

Liminatus Pharma gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Liminatus Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.